Open-label, Phase I Study of Nivolumab Combined with <i>nab</i> -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Abstract

The safety profile of nivolumab plus <i>nab</i>-paclitaxel and gemcitabine at standard doses in advanced pancreatic cancer was manageable, with no unexpected safety signals. Overall, the clinical results of this study do not support further investigation.